A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Subjects With T2DM Treated With Insulin.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
Most Recent Events
- 02 Dec 2010 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 02 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.